HBV Spring 2020: State of the Research


Take our post-test to claim CME credits.

To read a companion newsletter click here.

Why has finding a cure for hepatitis B infection been so challenging? What is it about this virus and its life cycle that makes it so different from curable HCV? In this issue, Dr. Marion Peters from the University of California San Francisco and Northwestern University explains the obstacles researchers face in their quest to tame this virus. 

Treating HCV in PWID: Best Practices

Take our post-test to claim CME credits.

To read a companion newsletter click here.

Hepatitis C has become “curable” for >90% of those infected. But while universal HCV elimination is medically possible, this goal is compromised by certain populations who remain underscreened, undertreated, and underserved and continue to spread the virus. One such population is people who inject drugs (PWID).   

In this issue, Dr. Brianna Norton and Dr. Matthew Akiyama from the Albert Einstein College of Medicine analyze the most important data to explain how substance use impacts adherence and the risk of HCV reinfection.

HCV: Management Beyond the Liver

Take our post-test to claim CME credits.

To read a companion newsletter click here.

The extrahepatic manifestations of chronic HCV can affect many different organ systems. In this eViralHepatitis Review podcast, Dr. Rajender Reddy from the University of Pennsylvania’s Perelman School of Medicine discusses clinical approaches to identifying and managing the effects of HCV infection beyond the liver.

Avoiding “MELD Purgatory”

Volume 6, Issue 8

In this issue, Drs. Jordan Feld and Lisette Krassenburg from the Toronto Centre for Liver Disease at the University of Toronto apply the information in their recent newsletter issue to clinical practice.

Take our post-test to claim CME credits.

To read a companion newsletter click here

Clinical Perspectives on Barriers To HBV Care

Volume 6, Issue 6

In this podcast follow-up to their recent eViralHepatitis Review newsletter issue (Vol. 6, No. 5), Dr. Mandana Khalili and Dr. Michele Tana from the University of California, San Francisco discuss how their analysis of the newer published information can impact clinical practice.

Take our post-test to claim CME credits.

To read a companion newsletter click here

Clinical Insight: Engaging PWID in HCV Care

Volume 6, Issue 4.

People who inject drugs (PWID) comprise a rapidly growing population of HCV-infected people who have historically been difficult to reach and treat. But without engagement in HCV care, PWID will continue to transmit the virus and impede efforts for hepatitis C eradication.

In this issue, Dr. Arthur Kim from Massachusetts General Hospital and Harvard Medical School provides a clinical perspective on identifying and overcoming the barriers that prevent PWID from effectively receiving HCV treatment.

Take our post-test to claim CME credits.

To read a companion newsletter click here.

In the Clinic: Identifying & Managing HCV Complications

Volume 6, Issue 2.

In this podcast Andrea Granados, MD describes the clinical impact of the early diagnosis of glucose abnormalities in people with CF, summarizes the limitations of alternative modalities for screening and diagnosing CFRD, and and identifies the current recommendations for the management of CFRD.

Take our post-test to claim CME credits.

To read a companion newsletter click here.

New Options for Patients with “Hard-To-Treat” Hepatitis C Infection

Volume 5, Issue 12.

In this podcast Dr. Ira Jacobson discusses New Options for Patients with “Hard-To-Treat” Hepatitis C Infection.

Take our post-test to claim CME credits:
Physician post-test
Nurse post-test

To read a companion newsletter click here.

Using Real World Data to Individualize HCV Management

Volume 5, Issue 10.

In this podcast Dr. David Wyles discusses managing DAA failures with the newly approved treatment options for hepatitis C.

Take our post-test to claim CME credits:
Physician post-test
Nurse post-test

To read a companion newsletter click here.

Using Real World Data to Individualize HCV Management

Volume 5, Issue 8.

In this podcast, Andrew J. Muir, MD from Duke University School of Medicine discusses the real-world data to support a sofosbuvir-ledipasvir treatment duration of 8 weeks versus 12 weeks, summarizes the current hepatitis C treatment options for patients with advanced kidney disease, and describes the risks and benefits of hepatitis C therapies in HIV-HCV coinfected patients.

Take our post-test to claim CME credits:
Physician post-test
Nurse post-test

To read a companion newsletter click here.